表观遗传调节因子ALKBH5促进肝细胞癌细胞对索拉非尼治疗的早期适应
The epigenetic regulator ALKBH5 facilitates the early adaptation of hepatocellular carcinoma cells to sorafenib treatment
Meng Li, Jiayu Wang, Shuai Fang, Lu Dai, Xilin Sun, Fei Sun, Wei Huang
Journal:JOURNAL OF CHEMOTHERAPY
IF:2.1
DOI:10.1080/1120009X.2026.2722741
PMID:42691501
Published:2026-09-03
research field:分子生物学药理学细胞生物学炎症研究结构生物学骨科生物化学
Abstract
Hepatocellular carcinoma (HCC) frequently develops resistance to tyrosine kinase inhibitors (TKIs) like sorafenib – the first FDA-approved systemic therapy for advanced HCC – yet early resistance mechanisms remain unclear. Short-term sorafenib exposure in sensitive HCC cells induces global m6A reduction and rapid upregulation of the demethylase ALKBH5. High ALKBH5 expression correlates with poor prognosis in sorafenib-treated HCC patients. Functionally, ALKBH5 overexpression enhances sorafenib resistance, clonogenicity and epithelial-mesenchymal transition (EMT) by stabilizing β-catenin and activating Wnt/β-catenin signalling. Thus, ALKBH5 is a key early driver of sorafenib resistance via the Wnt/β-catenin pathway and may serve as both a prognostic biomarker and therapeutic target in HCC.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


